KR850002480A - 피라졸-환 알킬화된 피라졸로 퀴놀린의 제조방법 - Google Patents

피라졸-환 알킬화된 피라졸로 퀴놀린의 제조방법 Download PDF

Info

Publication number
KR850002480A
KR850002480A KR1019840005148A KR840005148A KR850002480A KR 850002480 A KR850002480 A KR 850002480A KR 1019840005148 A KR1019840005148 A KR 1019840005148A KR 840005148 A KR840005148 A KR 840005148A KR 850002480 A KR850002480 A KR 850002480A
Authority
KR
South Korea
Prior art keywords
trans
propyl
quinoline
pyrazolo
alkyl
Prior art date
Application number
KR1019840005148A
Other languages
English (en)
Other versions
KR870001159B1 (ko
Inventor
메너트 샤우스 존 (외 2)
Original Assignee
아더 알. 웨일
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아더 알. 웨일, 일라이 릴리 앤드 캄파니 filed Critical 아더 알. 웨일
Publication of KR850002480A publication Critical patent/KR850002480A/ko
Application granted granted Critical
Publication of KR870001159B1 publication Critical patent/KR870001159B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

내용 없음

Description

피라졸-환 알킬화된 피라졸로 퀴놀린의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 일반식(ⅩⅩⅡ)의 화합물을 NH2NH2또는 그의 염 또는 수화물과 반응시키고; 임의로 생성물을 그의 트란스-(-)- 및 트란스-(+)-입체 이성체로 분할하고; 임의로 생성물을 그의 약제학적으로 허용되는 산부가염으로 전환시킴을 특징으로 하여, 일반식(Ⅹ) 및 (ⅩⅠ)의 트란스-(±)-토오토머 혼합물 및 그의 약제학적으로 허용되는 산부가염을 제조하는 방법.
    상기식에서, R은 H, CN, C1-C3알킬 또는 알릴이고; R1은 C1-C|3알킬이며; R2는 C1-C3알킬, 알릴 또는 CN이다.
  2. 일반식(ⅩⅩⅢ)의 화합물을 NH2NH2또는 그의 염 또는 수화물과 반응시키고; 임의로 생성물을 그의 트란스-(-)- 및 트란스 -(+)-입체 이성체로 분할하고; 임의로 생성물을 그의 약제학적으로 허용되는 산부가염으로 전환시킴을 특징으로 하여, 일반식(ⅩⅡ) 및 (ⅩⅢ)의 트란스-(±)-토오토머 혼합물 및 그의 약제학적으로 허용되는 산부가염을 제조하는 방법.
    상기식에서, R은 H, CN, C1-C3알킬 또는 알릴이고; R1a는 H 또는 C1-C-3알키이며; R2는 C1-C3알킬, 알릴 또는 CN이다.
  3. 일반식(ⅩⅩⅠⅩ) 및 (ⅩⅩⅩ)의 트란스-(±)-토오토머 화합물을 레니(Raney) 니켈과 반응시키고; 임의로 생성물을 그의 트란스-(-)- 및 트란스-(+)-입체 이성체로 분할하고; 임의로 생성물을 그의 약제학적으로 허용되는 산부가염으로 전환시킴을 특징으로 하여, 다음 일반식(ⅩⅡ) 또는 (ⅩⅢ)의 트란스-(±)-토오토머 혼합물 및 그의 약제학적으로 허용되는 산부가염을 제조하는 방법.
    상기식에서, R은 C1-C3알킬 또는 알릴이고; R1a는 H 또는 C1-C|3알킬이다.
  4. 제1항 내지 3항중 어느 하나에 있어서, 출발물질이 트란스-(-)- 또는 트란스-(+)-입체 이성체인 방법.
  5. 제1항에 있어서, 트란스-(±)-1-n-프로필-6-옥소-7-아세틸-데카하이드로 퀴놀린을 하이드라진과 반응시킴을 특징으로 하여, 트란스-(±)-3-메틸-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로-1H-(및 2H) 피라졸로[3,4-g] 퀴놀린을 제조하는 방법.
  6. 제1항에 있어서, 트란스-(±)-1-n-프로필-6-옥소-7-프로피오닐-테카하이드로 퀴놀린을 하이드라진과 반응시킴을 특징으로 하여, 트란스-(±)-3-에틸-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타-하이드로-1H(및 2H)피라졸로[3,4-g]퀴놀린을 제조하는 방법.
  7. 제1항에 있어서, 트란스-(±)-1-n-프로필-6-옥소-7-부티릴 데카하이드로 퀴놀린을 하이드라진과 반응시킴을 특징으로 하여, 트란스-(±)-3,5-디-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로-1H(및 2H)피라졸로[3,4-g]퀴놀린을 제조하는 방법.
  8. 제2항에 있어서, 트란스-(±)-1-n-프로필-5-아세틸-6-옥소 데카하이드로 퀴놀린을 하이드라진과 반응시킴을 특징으로 하여, 트란스-(±)-1-메틸-6-n-프로필-4,5,5a,6,7,8,9,9a-옥타하이드로-2H(및 3H) 피라졸로[4,3-f]퀴놀린을 제조하는 방법.
  9. 제2항에 있어서, 트란스-(±)-1-n-프로필-5-프로피오닐-6-옥소 메카하이드로 퀴놀린을 하이드라진과 반응시킴을 특징으로 하여, 트란스-(±)-1-에틸-6-n-프로필-4,5,5a,6,7,8,9,9a-옥타하이드로-2H(및 3H) 피라졸로[4,3-f]퀴놀린을 제조하는 방법.
  10. 제2항에 있어서, 트란스-(±)-1-n-프로필-5-부티릴-6-옥소데카하이드로 퀴놀린을 하이드라진과 반응시킴을 특징으로 하여, 트란스-(±)-1,6-디-n-프로필-4,5,5a,6,7,8,9,9a-옥타하이드로-2H(및 3H)피라졸로[4,3-f]퀴놀린을 제조하는 방법.
  11. 제3항에 있어서, 트란스-(±)-4-스피로-1',3'-티올아노-6-n-프로필-4,5,5a,6,7,8,9,9a-옥타하이드로-2H(및 3H) 피라졸로[4,3-f]퀴놀린을 레니니켈과 반응시킴을 특징으로 하여, 트란스-(±)-6-n-프로필-4,5,5a,6,7,8,9,9a-옥타 하이드로-2H(및 3H) 피라졸로[4,3-f]퀴놀린을 제조하는 방법.
    참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019840005148A 1983-09-26 1984-08-24 피라졸-환 알킬화된 피라졸로 퀴놀린의 제조방법 KR870001159B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53551983A 1983-09-26 1983-09-26
US535519 1983-09-26
US535,519 1983-09-26

Publications (2)

Publication Number Publication Date
KR850002480A true KR850002480A (ko) 1985-05-13
KR870001159B1 KR870001159B1 (ko) 1987-06-13

Family

ID=24134591

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840005148A KR870001159B1 (ko) 1983-09-26 1984-08-24 피라졸-환 알킬화된 피라졸로 퀴놀린의 제조방법

Country Status (10)

Country Link
EP (1) EP0145121B1 (ko)
JP (4) JPS6110583A (ko)
KR (1) KR870001159B1 (ko)
CA (1) CA1270488A (ko)
DE (1) DE3484925D1 (ko)
DK (1) DK400884A (ko)
GB (1) GB2146984B (ko)
GR (1) GR80200B (ko)
HU (1) HU199836B (ko)
IL (1) IL72729A (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6392722A (ja) * 1986-10-03 1988-04-23 Unitika Ltd 熱接着繊維およびその不織布
JPS6392723A (ja) * 1986-10-06 1988-04-23 Unitika Ltd 湿潤性複合繊維およびその不織布
JPS6420322A (en) * 1987-07-13 1989-01-24 Mitsubishi Petrochemical Co Conjugated fiber
JPH01204617A (ja) * 1988-02-09 1989-08-17 Chisso Corp 敷物
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
KR20000008130A (ko) * 1998-07-10 2000-02-07 조정래 폴리에스터계 탄성사용 공중합물의 제조방법
WO2012094618A1 (en) 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
WO2013130420A1 (en) * 2012-02-27 2013-09-06 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3848027T3 (pl) 2013-11-25 2023-07-24 Corcept Therapeutics Incorporated Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020132023A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
BR112021015129A2 (pt) 2019-02-22 2021-09-28 Corcept Therapeutics Incorporated Método para tratar um paciente que sofre de hipercortisolemia e um sintoma ou comorbidade da mesma
EP4072556A4 (en) 2019-12-11 2024-01-03 Corcept Therapeutics Incorporated METHOD FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN WITH MIRICORILANT

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198415A (en) * 1979-01-22 1980-04-15 Eli Lilly And Company Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines
US4230861A (en) * 1979-01-22 1980-10-28 Eli Lilly And Company 1-And/or 7-substituted-6-hydroxy (or oxo)-3-decahydroquinoline carboxylic acids
SU776048A1 (ru) * 1979-06-05 1983-09-23 Институт Бисорганической Химии Ан Бсср Производные 8-аза-16-оксагона-17-онов, про вл ющие противовоспалительную,мембраностабилизирующую и антифибринолитическую активность,и способ их получени
US4252945A (en) * 1979-07-11 1981-02-24 E. R. Squibb & Sons, Inc. Process for preparing pyrazolo[1,5-c]-quinazoline derivatives and novel intermediates
US4367231A (en) * 1979-09-14 1983-01-04 Eli Lilly And Company Method of using octahydro pyrazolo[3,4-g]quinolines
ES8504174A1 (es) * 1982-11-03 1985-04-16 Lilly Co Eli Un procedimiento para la preparacion de derivados de pirazolo-quinolinas.

Also Published As

Publication number Publication date
GB2146984A (en) 1985-05-01
HU199836B (en) 1990-03-28
GR80200B (en) 1985-01-02
DK400884A (da) 1985-03-27
KR870001159B1 (ko) 1987-06-13
GB8421159D0 (en) 1984-09-26
EP0145121A3 (en) 1988-04-27
JPH05194511A (ja) 1993-08-03
EP0145121B1 (en) 1991-08-14
CA1270488A (en) 1990-06-19
DK400884D0 (da) 1984-08-22
GB2146984B (en) 1987-04-08
DE3484925D1 (de) 1991-09-19
JPH0568475B2 (ko) 1993-09-29
JPH0660183B2 (ja) 1994-08-10
JPH05194527A (ja) 1993-08-03
EP0145121A2 (en) 1985-06-19
IL72729A (en) 1988-02-29
JPS6110583A (ja) 1986-01-18
IL72729A0 (en) 1984-11-30
JPH0625251A (ja) 1994-02-01
HUT34750A (en) 1985-04-28

Similar Documents

Publication Publication Date Title
KR850002480A (ko) 피라졸-환 알킬화된 피라졸로 퀴놀린의 제조방법
JPS6089474A (ja) モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤
KR870003998A (ko) 퀴나졸린 유도체류의 제조방법
KR850002469A (ko) 피세나돌 전구체 및 그의 중간체의 제조방법
KR850003393A (ko) 1-벤질-아미노알킬-피롤리디논의 제조방법
KR870011145A (ko) 퀴놀린 카르본산 유도체의 제법
ES394913A1 (es) Procedimiento para la preparacion de nuevos 1-fenoxi-2-hi- droxi - 3 - alcohilaminopropanos racemicos u opticamente ac-tivos.
KR840007579A (ko) 신규 니트로 알리파틱화합물의 제조방법
KR840006009A (ko) 티에노 피리미딘 유도체 및 이의 산부가염의 제조방법
JPS6114148B2 (ko)
US4086349A (en) Quinolopyran-4-one-2-carboxylic acid derivatives and salts thereof as novel compounds and as medicines for treatment of allergic asthma
DE3266943D1 (en) Chroman compounds, process for producing them and pharmaceutical compositions containing them
KR850004481A (ko) 4, 5-디하이드로-6-[2-[4-(1h-이미다졸-1-일)페닐]-에테닐]-3(2h)-피리다지논류의 제법
DE3272824D1 (en) Novel substituted imidazoles and triazoles, fungicidal compositions containing them, the use thereof for combating fungi and processes for the preparation of intermediates for making the imidazoles and triazoles
KR840005449A (ko) 벤조티오 피라노 피리디논
KR840001974A (ko) 1-[3-(6-플루오로-1,2-벤즈이속사졸-3-일)프로필]-4-(치환된)-피페라진 및-피레리딘의 제조방법
US4261998A (en) Tetrahydro-isoquinoline derivatives
KR850001215A (ko) 5-치환된 [1,2,4]트리아졸로-[1,5-c]피리미딘-2-아민의 제조방법
KR860003204A (ko) 디페닐메틸이민 유도체의 제조방법
JPS5740479A (en) Preparation of benzofuran derivative and its acid addition salt
GB1512653A (en) Indazoles and the like
KR840006654A (ko) 트랜스-4aR-5-n-프로필-4,4a,5,6,7,8,8a,9-옥타하이드로-1H(및 2H)피라졸로[3,4-g]퀴놀린의 제조방법
ES8506606A1 (es) Procedimiento de preparacion de eteres oximas basicos y de sus sales de adicion acidas
Wagner et al. Resonance and Hydrogen Bond Effects on the Basic Strengths of Certain Arylalkyl Azomethines
KR840002848A (ko) 유기인산염의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19930329

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee